BioCryst Pharmaceuticals Inc. Sets New 1-Year High at $10.87 (BCRX)
Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) hit a new 52-week high during mid-day trading on Monday, Analyst Ratings News reports. The stock traded as high as $10.87 and last traded at $10.54, with a volume of 1,736,468 shares trading hands. The stock had previously closed at $10.08.
BCRX has been the subject of a number of recent research reports. Analysts at JMP Securities reiterated a “market perform” rating on shares of BioCryst Pharmaceuticals in a research note to investors on Monday. Separately, analysts at Thomson Reuters/Verus downgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note to investors on Tuesday, December 24th. Finally, analysts at MLV Capital raised their price target on shares of BioCryst Pharmaceuticals from $6.50 to $9.00 in a research note to investors on Thursday, December 19th. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. BioCryst Pharmaceuticals presently has an average rating of “Hold” and an average price target of $9.00.
BioCryst Pharmaceuticals has a 1-year low of $1.12 and a 1-year high of $10.14. The stock’s 50-day moving average is $7.01 and its 200-day moving average is $5.74. The company’s market cap is $621.0 million.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings data on Tuesday, November 5th. The company reported ($0.14) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.14). The company had revenue of $2.40 million for the quarter, compared to the consensus estimate of $2.01 million. During the same quarter in the prior year, the company posted ($0.19) earnings per share. The company’s quarterly revenue was down 58.8% on a year-over-year basis. On average, analysts predict that BioCryst Pharmaceuticals will post $-0.53 earnings per share for the current fiscal year.
BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) is a biotechnology company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.